Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Antineoplastic Agents

All Drugs and Chemicals

Gefitinib

Long term survivors who has been used IRESSA for more than 3 years and are still on gefitinib treatment

Long term survivors who has been used IRESSA for more than 3 years but have already terminated from EAP

Fast-progressors who defined as no more than 1 follow-up visit after recruitment with the reason of discontinuation being

Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.

EGFR Mutation Test

Ki-67 protein expression in tissue will be analysed by IHC method.

Ki-67 protein expression

Karen Atkin

Louis Zhang

Longyun Li

The primary objective is to describe the quality of life of long-term survivors who are not terminated from the EAP.

A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

An International Expanded Access Clinical Programme With ZD1839 (IRESSATM) for Patients With Advanced Non-small Cell Lung Cancer (NSCLC) China Amendment 1: A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa

AstraZeneca

MC MD

Blood and Lymph Conditions

Rare Diseases

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Neoplasms by Histologic Type

Hematologic Diseases

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Acute Graft Versus Host Disease

Amino Acids

Midostaurin

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)

The purpose of this study is to provide access to Midostaurin and gather additional safety data on the combination of Midostaurin and standard of care for adult patients with newly diagnosed Fms-like tyrosine kinase receptor (FLT3) mutated Acute Myeloid Leukemia (AML) who are eligible for standard induction and consolidation chemotherapy.

The purpose of this study is to provide Midostaurin (study drug) treatment to newly diagnosed FLT3 mutated (ITD or TKD) AML adult patients (18 years or older) eligible for standard standard induction (cytarabine + daunorubicin/Idarubicin) and consolidation (cytarabine) chemotherapy.

Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy

An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.

Novartis Pharmaceuticals

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Myotonic Dystrophy Type 1

Fibrinolytic Agents

Anti-Arrhythmia Agents

Vasodilator Agents

Analgesics

Ado-Trastuzumab Emtansine

Trastuzumab

Tissue Plasminogen Activator

Adenosine

Antineoplastic Agents, Immunological

Immunotoxins

Immunoconjugates

Immunologic Factors

Tubulin Modulators

Antimitotic Agents

trastuzumab-MCC-DM1

Clinical Trials

This is a multicenter, open-label, single-arm, expanded access study designed to provide T-DM1 to patients with HER2-positive locally advanced or metastatic breast cancer and to evaluate the safety and efficacy of T-DM1 administered by intravenous (IV) infusion.

A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer

Genentech, Inc.

Heart and Blood Diseases

Immune System Diseases

Multiple Myeloma

Neoplasms, Plasma Cell

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Idecabtagene vicleucel

Nonconforming idecabtagene vicleucel is to be administered to participants after lymphodepleting chemotherapy

Nonconforming idecabtagene vicleucel

Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,

First line of the email MUST contain the NCT# and Site #.

Bristol-Myers Squibb

This study is designed to evaluate the safety and efficacy of nonconforming idecabtagene vicleucel (ide-cel) in participants with multiple myeloma per the approved prescribing information. This is an expanded access protocol (EAP) to be conducted at Risk Evaluation and Mitigation Strategies (REMS) qualified sites approved for commercial administration of idecabtagene vicleucel and where the EAP is authorized to be conducted for use of nonconforming idecabtagene vicleucel.

Non-conforming idecabtagene vicluecel is idecabtagene vicleucel that does not meet commercial release specifications but may be acceptable for use as an investigational product in the Expanded Access Protocol setting.

Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Expanded Access Protocol (EAP) for Patients Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release

Celgene

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa	NCT01000740	Non-small Cell ...	EGFR Mutation T... Ki-67 protein e...	-	AstraZeneca
Midostaurin Access Program for Newly Diagnosed FLT3 (ITD or TKD) Mutated AML Adult Patients Eligible for Standard Induction and Consolidation Chemotherapy	NCT02624570	Acute Myeloid L... FLT3 Mutation, ...	Midostaurin	18 Years -	Novartis
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer	NCT01120561	Metastatic Brea...	trastuzumab-MCC...	18 Years -	Genentech, Inc.
Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial Release	NCT04771078	Multiple Myelom...	Nonconforming i...	18 Years -	Celgene
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer	NCT01120561	Metastatic Brea...	trastuzumab-MCC...	18 Years -	Genentech, Inc.
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa	NCT01000740	Non-small Cell ...	EGFR Mutation T... Ki-67 protein e...	-	AstraZeneca
A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa	NCT01000740	Non-small Cell ...	EGFR Mutation T... Ki-67 protein e...	-	AstraZeneca

Spots Global Cancer Trial Database for eap

Every month we try and update this database with for eap cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for eap

Every month we try and update this database with for eap cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for eap cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.